197 related articles for article (PubMed ID: 36759199)
1. PSMA-GCK01: A Generator-Based
Cardinale J; Giesel FL; Wensky C; Rathke HG; Haberkorn U; Kratochwil C
J Nucl Med; 2023 Jul; 64(7):1069-1075. PubMed ID: 36759199
[TBL] [Abstract][Full Text] [Related]
2. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [
Mamlins E; Scharbert L; Cardinale J; Krotov M; Winter E; Rathke H; Strodel B; Ankrah AO; Sathekge M; Haberkorn U; Kratochwil C; Giesel FL
Mol Imaging Biol; 2024 Feb; 26(1):81-89. PubMed ID: 38066252
[TBL] [Abstract][Full Text] [Related]
3. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of
Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
[TBL] [Abstract][Full Text] [Related]
5. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of
Pham TT; Hungnes IN; Rivas C; Cleaver J; Firth G; Blower PJ; Sosabowski J; Cook GJR; Livieratos L; Young JD; Pringle PG; Ma MT
J Nucl Med; 2024 Jun; ():. PubMed ID: 38844360
[TBL] [Abstract][Full Text] [Related]
6. Head to head comparison performance of
García-Pérez FO; Davanzo J; López-Buenrostro S; Santos-Cuevas C; Ferro-Flores G; Jímenez-Ríos MA; Scavuzzo A; Santana-Ríos Z; Medina-Ornelas S
Am J Nucl Med Mol Imaging; 2018; 8(5):332-340. PubMed ID: 30510850
[TBL] [Abstract][Full Text] [Related]
7.
Santos-Cuevas C; Davanzo J; Ferro-Flores G; García-Pérez FO; Ocampo-García B; Ignacio-Alvarez E; Gómez-Argumosa E; Pedraza-López M
Nucl Med Biol; 2017 Sep; 52():1-6. PubMed ID: 28575794
[TBL] [Abstract][Full Text] [Related]
8.
Santos-Cuevas C; Ferro-Flores G; García-Pérez FO; Jiménez-Mancilla N; Ramírez-Nava G; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Davanzo J; Soldevilla-Gallardo I
Contrast Media Mol Imaging; 2018; 2018():5247153. PubMed ID: 30534027
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Development and Characterization of
Bolzati C; Gobbi C; Ferro-Flores G; Turato S; Ocampo-Garcia B; Carpanese D; Marzano C; Spolaore B; Fracasso G; Rosato A; Meléndez-Alafort L
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203663
[TBL] [Abstract][Full Text] [Related]
12.
Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry estimation and preliminary clinical application of [
Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Radiation dosimetry of
Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
Sci Rep; 2020 Mar; 10(1):4179. PubMed ID: 32144340
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
19. Preparation and Biological Evaluation of [
Xiao D; Duan X; Gan Q; Zhang X; Zhang J
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
